Skip to content
Labcoat
  • Investors
  • Insights
  • Login

JOIN THE COMMUNITY

Labcoat
  • Investors
  • Insights
  • Login

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Biotech Hub / By Sal Daher, CFA

Click the image to the left and log in to get your exclusive reader perks.
https://www.thedailytimes.com/business/graphite-bio-presents-overview-of-phase-1-2-cedar-trial-evaluating-investigational-gene-editing-therapy/article_233a0269-7f07-54be-835c-c9a01e489f30.html

Post navigation
← Previous Post
Next Post →

Related Posts

Investors see promise in digital health — the challenge is adoption

Biotech Hub

Health care workers say this is not the time to wait for a flu shot

Biotech Hub / By Sal Daher, CFA

Subscribe to Newsletter

Labcoat Ventures

We work with angel investors to fund the most promising early-stage biotechs.

Copyright © 2025

  • Investors
  • Insights
  • Biotech Hub